[1] Villadsen LS, Skov L, Baadsgaard O. Biological response modifiers and their potential use in the treatment of inflammatory skin diseases. Exp Dermatol, 2003, 12:1-10.
[2] Willems M, Munte K, Vrolijk JM, et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol, 2003, 149:390-394.
[3] Dereure O, Raison-Peyron N, Larrey D, et al. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C:a series of 20 patients. Br J Dermatol, 2002, 147:1142-1146.
[4] Tursen U, Kaya TI, Ikizoglu G. Interferonalpha 2b induced facial erythema in a woman with chronic hepatitis C infection. J Eur Acad Dermatol Venereol, 2002, 16:285-286.
[5] Wendling J, Descamps V, Grossin M, et al.Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C. Arch Dermatol, 2002,138:546-547.
[6] Stafford-Fox V, Guindon KM. Cutaneous reactions associated with alpha interferon therapy. Clin J Oncol Nurs, 2000, 4:164-168.
[7] Sanders S, Busam K, Tahan SR, et al.Granulomatous and suppurative dermatitis at interferon alfa injection sites:report of 2cases. J Am Acad Dermatol, 2002, 46:611-616.
[8] Sampaio EP, Moreira AL, Sarno EN, et al.Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med, 1992, 175:1729-1737.
[9] Mazzeo L, Ricciardi L, Fazio MC, et al. Severe urticaria due to recombinant interferon beta-1a. Br J Dermatol, 2003, 148:172.
[10] van Rengen A, Goossens A. Local reactions after subcutaneous injections of beta-interferon. Contact Dermatitis, 1998, 39:209.
[11] Cohen BA, Greenberger PA, Saini S. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. Allergy Asthma Proc,1998, 19:85-88.
[12] Sheremata WA, Taylor JR, Elgart GW.Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med, 1995, 332:1584.
[13] Yamashita N, Natsuaki M, Morita H, et al.Cutaneous eruptions induced by granulocyte colony-stimulating factor in two cases of acute myelogenous leukemia. J Dermatol,1993, 20:473-477.
[14] Robak E, Robak T, Gora-Tybor J, et al.Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. J Med, 2001, 32:31-39.
[15] Samlaska CP, Noyes DK. Localized cutaneous reactions to granulocyte colony-stimulating factor. Arch Dermatol, 1993, 129:645-646.
[16] Andavolu MV, Logan LJ. Leukocytoclastic vasculitis as a complication of granulocyte colony-stimulating factor (G-CSF)-a case study. Ann Hematol, 1999, 78:79-81.
[17] Farina MC, Requena L, Domine M, et al.Histopathology of cutaneous reaction to granulocyte colony-stimulating factor:another pseudomalignancy. J Cutan Patrol,1998, 25:559-562.
[18] Bachmeyer C, Chaibi P, Aractingi S. Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor. Br J Dermatol, 1998, 139:354-355.
[19] Arbetter KR, Hubbard KW, Markovic SN,et al. Case of granulocyte colony-stimulating factor-induced Sweet's syndrome. Am J Hematol, 1999, 61:126-129.
[20] Scott GA. Report of three cases of cutaneous reactions to granulocyte macrophagecolony-stimulating factor and a review of the literature. Am J Dermatopathol, 1995,17:107-114.
[21] Passweg J, Buser U, Tichelli A, et al. Pustular eruption at the site of subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor.Ann Hematol, 1991, 63:326-327.
[22] Hardwick N, King CM. Generalized eczematous reaction to erythropoietin. Contact Dermatitis, 1993, 28:123.
[23] Cuxart M, Just M, Sans R, et al. Generalized exfoliative dermatitis caused by erythropoietin. Med Clin (Barc), 2000, 115:158.
[24] Prussick R, Horn TD, Wilson WH, et al. A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1 alpha. J Am Acad Dermatol,1996, 35705-35709.
[25] O'Reilly F, Feldman E, Yang J, et al. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. J Am Acad Dermatol, 2003, 48:602-604.
[26] Segura Huerta AA, Tordera P, Cercos AC,et al. Toxic epidermal necrolysis associated with interleukin-2. Ann Pharmacother,2002, 36:1171-1174.
[27] Bernand S, Scheidegger EP, Dummer R, et al. Multifocal fixed drug eruption to paracetamol, tropisetron and ondansetron induced by interleukin 2. Dermatology, 2000,201:148-150.
[28] Bridges AG, Helm TN, Bergfeld WF, et al.Interleukin-3-induced urticaria-like eruption. J Am Acad Dermatol, 1996, 34:1076-1078.
[29] Fleming TE, Mirando WS, Soohoo LF, et al.An inflammatory eruption associated with recombinant human IL-6. Br J Dermatol,1994, 130:534-536.
[30] Newton S, Jackowski C, Marrs J. Biotherapy skin reaction. Clin J Oncol Nurs, 2002, 6:181-182.
[31] Griffiths CE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol,2003, 17:1-5.
[32] Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J Drugs Dermatol, 2003, 2:570-573.
[33] Sasaki O, Yokoyama A, Uemura S, et al. Drug eruption caused by recombinant human GCSF. Intern Med, 1994, 33:641-643. |
